Sio Capital Management LLC Acquires Shares of 1,433,155 Annexon, Inc. (NASDAQ:ANNX)

Sio Capital Management LLC bought a new position in Annexon, Inc. (NASDAQ:ANNX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,433,155 shares of the company’s stock, valued at approximately $8,484,000. Annexon makes up about 3.4% of Sio Capital Management LLC’s holdings, making the stock its 11th largest position. Sio Capital Management LLC owned about 1.36% of Annexon as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ANNX. Sandia Investment Management LP bought a new position in Annexon in the 2nd quarter valued at approximately $49,000. Victory Capital Management Inc. purchased a new stake in shares of Annexon during the second quarter valued at $51,000. Principal Financial Group Inc. purchased a new stake in shares of Annexon during the 2nd quarter valued at about $56,000. Comerica Bank bought a new position in Annexon during the first quarter valued at approximately $72,000. Finally, Bayesian Capital Management LP purchased a new stake in Annexon in the first quarter worth approximately $119,000.

Insiders Place Their Bets

In related news, EVP Ted Yednock sold 5,408 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total value of $40,073.28. Following the completion of the transaction, the executive vice president now owns 71,365 shares of the company’s stock, valued at approximately $528,814.65. This represents a 7.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 15,408 shares of company stock worth $103,043. Company insiders own 12.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on ANNX. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Annexon has a consensus rating of “Buy” and a consensus price target of $15.80.

Annexon Stock Up 0.9 %

ANNX stock opened at $5.34 on Friday. The business’s 50-day moving average price is $6.65 and its 200-day moving average price is $5.95. The stock has a market cap of $569.21 million, a P/E ratio of -5.09 and a beta of 1.23. Annexon, Inc. has a twelve month low of $2.27 and a twelve month high of $8.40.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.